Atlas Trials

Umbilical Cord Blood-Derived Natural Killer Cells, Elotuzumab, Lenalidomide, and High Dose Melphalan, Followed by Stem Cell Transplant in Treating Patients With Multiple Myeloma

Clinical trial NCT01729091 · COMPLETED

Trial details

NCT number
NCT01729091
Sponsor
M.D. Anderson Cancer Center
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Plasma Cell LeukemiaPlasma Cell Myeloma
Start date
2013-06-10
Primary completion
2024-06-25
Enrollment
72

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.